JLHL

Concall Schedule Concall Date: 16th November, 2026 Concall Time: 11:00 AM- 4:00 PM

Current scenario - Existing hospitals continue to perform in line with expectations with stable occupancies (Thane and Pune at ~70%). - Dombivli hospital ramp-up is continuing well with EBITDA loss narrowing sharply to INR20 lakhs in Q2 compared to INR9.5 crores in Q1, partly aided by seasonal infectious disease burden. - Total company income for Q2 stood at INR456.5 crores, EBITDA at INR106.9 crores, and PAT at INR56.4 crores. Changes in trends - Board approved acquisition of land currently leased for the Pune South hospital for a total consideration of INR150 crores (incremental cash outflow of INR100 crores after adjusting INR50 crores deposit). - Occupancy for H1 FY27 stands at 59.5% overall and 64.8% excluding Dombivli. - ARPOB stood at INR71,800 and IP ARPOB at INR58,700 for the quarter. Management Guidance & Outlook - Management maintains a conservative outlook on Dombivli break-even timelines and continues ongoing doctor hirings across units. - Board has a self-imposed debt ceiling of 3x EBITDA. - Mira Bhayandar is in the regulatory stage with activities expected to commence before the end of the financial year, while BKC is in the planning stage.

- Jupiter Life Line Hospitals Limited informed the exchanges about the audio link of the analyst/investor conference call for Q2 & H1 FY27 held on October 26, 2026. - The audio recording is made available on the company website.

Q2 FY27 Standalone Revenue ₹377.5 Cr vs ₹327.1 Cr (▲15% YoY) PAT ₹51.5 Cr vs ₹54.6 Cr (▼6% YoY) Board approved entering into a sale agreement for acquisition of ~11,452.07 sq. metres of land in Bibvewadi, Pune for ₹150 Crores Board approved the incorporation of a wholly owned subsidiary

- Q2 FY27 Total Income grew 16.0% YoY to ₹456.5 Cr; EBITDA rose 15.9% YoY to ₹106.9 Cr. - PAT stood at ₹56.4 Cr, down 1.7% YoY due to higher finance and depreciation costs. - Board approved acquisition of Pune South hospital land for ₹150 Cr. - Dombivli hospital ramp-up narrowed EBITDA loss to ₹0.2 Cr.

Q2 FY27 Standalone Revenue ₹364.6Cr vs ₹315.8Cr (▲15% YoY) EBITDA ₹94.1Cr vs ₹78.8Cr (▲19% YoY) PAT ₹51.5Cr vs ₹54.6Cr (▼6% YoY) EBITDA Margin 25.8% vs 25.0% (▲80bps) Board approved land acquisition of ~11,452.07 sq m at South Pune for ₹150 Cr and incorporation of a wholly owned subsidiary.

- Approved unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. - Approved the incorporation of a wholly-owned subsidiary. - Approved the acquisition of ~11,452.07 sq. metres of land at Bibvewadi, South Pune for ₹150 Crores.

- Jupiter Life Line Hospitals Limited executed a hypothecation agreement with HDFC Bank Limited on October 18, 2026. - Purpose: Financing the capital expenditure requirements of the company. - Loan Amount: Term Loan of ₹500 Crore with a sublimit of ₹300 Crore towards LC facility. - Security: Exclusive charge on Dombivli and Pune Baner hospitals and pari-passu charge on current assets.

Concall Schedule Concall Date: Monday, 26th October 2026 Concall Time: 10:00 AM IST

- Trading window closed with effect from October 01, 2026. - Reopens 48 hours after declaration of financial results for quarter and half year ending September 30, 2026. - Closure applies to all Designated Persons and their immediate relatives.

- Investor Conference Schedule - Concall Date: 28th September 2026 - Concall Time: 1:00 pm to 5:00 pm

- Q1 FY27 Consolidated performance: Total income ₹411 Cr, EBITDA ₹79.3 Cr (19.3% margin), PAT ₹37.5 Cr. - Dombivli Hospital: Completed first full quarter, contributed ₹9.5 Cr EBITDA drag as anticipated, with occupancy at 25-30%. Breakeven is still expected in 1.5-2 years, with oncology & radiation services launching by year-end. - Indore unit: Experienced lower Q1 EBITDA margin (12%) due to new hires for anticipated growth and is expected to grow faster than other units. - ARPOB grew 10% YoY driven by case mix improvement and contract renegotiations. - Net Debt: Company maintains effectively 0 net debt, with ~₹500 Cr debt and ~₹500 Cr cash. - Strategic Initiative: Acquired an IV fluid manufacturing plant for ₹35-40 Cr for backward integration to manage costs and improve margins. - Future Outlook: Focus on delivering 3 announced projects within the next 5 years, targeting Western India due to strong demand-supply gap in organized healthcare. - Pledged Shares: Clarified that the apparent increase in pledged shares was due to a 5x stock split, not new pledges, and was a non-promoter pledge; filing has been corrected.

- Audio link for Q1 FY27 Analyst/Investor Conference Call, held on August 3, 2026, is now available on the company website. - Link: jupiterhospital.com/wp-content/uploads/2026/08/earning-call-audio-recording-quarter1.mp3

- The Board of Directors on July 31, 2026, authorized Mr. Harshad Purani (CFO), in addition to Dr. Ankit Thakker (MD & CEO), for determining the materiality of events/information. - Ms. Suma Upparatti (Company Secretary & Compliance Officer) is authorized for disclosure to the Stock Exchanges.

- Consolidated Revenue ₹4,109.83Mn vs ₹3,529.53Mn (▲16.44% YoY) - EBITDA ₹792.69Mn vs ₹784.20Mn (▲1.08% YoY) - PAT ₹375.12Mn vs ₹439.45Mn (▼14.64% YoY) - EBITDA Margin 19.29% vs 22.22% (▼293bps) - Board approved the appointment of Mr. Harshad Purani as Chief Financial Officer and Key Managerial Personnel. - A subsidiary acquired 100% equity share capital of Sulcus Private Limited for ₹3.78 crore, making it a step-down subsidiary.

- Consolidated Revenue ₹410.98 Cr vs ₹352.95 Cr (▲16.44% YoY) - EBITDA ₹79.27 Cr vs ₹78.42 Cr (▲1.08% YoY) - PAT ₹37.51 Cr vs ₹43.95 Cr (▼14.64% YoY) - EBITDA Margin 19.29% vs 22.22% (▼293bps) - Board approved the appointment of Mr. Harshad Purani as Chief Financial Officer and Key Managerial Personnel. - Acquired 100% equity share capital of Sulcus Private Limited for ₹3.78 crore, making it a step-down wholly owned subsidiary.

- Consolidated Revenue ₹410.98 Cr vs ₹352.95 Cr (▲16.44% YoY) - EBITDA ₹79.27 Cr vs ₹78.42 Cr (▲1.08% YoY) - PAT ₹37.49 Cr vs ₹43.89 Cr (▼14.60% YoY) - EBITDA Margin 19.29% vs 22.22% (▼293bps) - Board approved the appointment of Mr. Harshad Purani as Chief Financial Officer and Key Managerial Personnel. - Company acquired 100% of the equity share capital of Sulcus Private Limited for ₹3.78 crore, making it a wholly-owned step-down subsidiary.